611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Cancer
Resources
Basic InformationLatest News
Cancer Treatment Can Affect Your Food PreferencesExpected Burden of Lung Cancer High for People Living With HIVNew Link Seen Between Gene Fusion and Bladder CancerSkin Cancer Prevention Strategies Needed in Work SettingsFDA Approves First Biosimilar Drug for CancerAliqopa Approved for Follicular LymphomaFibrous Dysplasia Associated With Increased Breast Cancer RiskU.S. Cancer Death Rate Continues to FallAACR Releases 2017 Cancer Progress ReportUSPSTF Backs Cervical Cancer Screening With Cytology or hrHPVMultivitamin Use May Cut Risk of Chemo-Induced NeuropathySurgeons Play Big Role in Women's Choices for Breast Cancer CareDabrafenib, Trametinib Beneficial in Resected MelanomaNew Guideline Aims to Help Doctors Diagnose Head, Neck MassesWidening Waistlines May Raise Women's Cancer RiskAdjuvant Nivolumab Tops Ipilimumab in MelanomaHPV Test Alone OK for Cervical Cancer Screening Over 30: Expert PanelCancer Drugs' High Prices Not Justified by Cost of Development, Study ContendsMedian Cost of Cancer Drug Development $648.0 MillionManaging Pain Can Be a Puzzle After Breast CancerImmune-Focused Drug May Be New Weapon Against Advanced MelanomaObamacare Paid Off for Poorer Cancer PatientsStrong Evidence for Healthy Lifestyle Reducing CRC RiskHere's the Recipe to Keep Colon Cancer at BayCRC Tumor Cells Exposed to Gut Bacteria Express ChemokinesUniversal Sequencing of Cancer Genes Ups Mutation DetectionMailed Invitations Increase CRC Screening CompletionInactivated Vaccinia Virus Shows Promise Against Advanced Cancer'Cancer Pen' Could Help Surgeons Spot Tumor Cells in SecondsCould the Zika Virus Help Battle a Deadly Brain Cancer?New Research Finds Value in PSA TestingHealth Tip: Diet and Activity May Help Prevent CancerFDA OKs Return of Once-Withdrawn Leukemia DrugLow Tumor Growth Rates During Active Surveillance of Thyroid CAScience Weighs in On How Fat Raises Cancer RiskFirst Gene Therapy Approved in U.S.Options Available for Estrogen Depletion After Breast CancerMoles Not Most Likely Spot for MelanomasAndrogen-Deprivation Therapy May Carry Cardiovascular RisksComputed Tomography Useful for Staging Head, Neck MelanomaCommon Treatment for Early Prostate Cancer May Carry Heart RiskCould Common Vitamin Supplements Raise Lung Cancer Risk?Females Show Better Response to CRT in Esophageal CancerOutdoor Nighttime Light Exposure Linked to Breast Cancer RiskArsenic Levels Higher in Patients With Nonmelanoma Skin CancersRadioiodine Therapy for Thyroid Cancer Doesn't Up Stroke RiskOne-Quarter With Early Breast Cancer Strongly Considers CPMFDA Approves New Treatment for Acute Lymphoblastic LeukemiaNew Treatment Approved for Deadly Blood CancerHigh-Cal Foods May Raise Cancer Risk in Women, Even Without Weight Gain
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Multivitamin Use May Cut Risk of Chemo-Induced Neuropathy


HealthDay News
Updated: Sep 13th 2017

new article illustration

WEDNESDAY, Sept. 13, 2017 (HealthDay News) -- Multivitamin use before diagnosis of breast cancer is associated with reduced risk of symptoms of chemotherapy-induced peripheral neuropathy, according to a study published online Sept. 1 in the Journal of the National Cancer Institute.

Gary R. Zirpoli, Ph.D., from the Roswell Park Cancer Institute in Buffalo, N.Y., and colleagues examined use of dietary supplements before and during treatment in relation to CIPN using data from questionnaires completed by 1,225 breast cancer patients. The authors assessed supplement use in relation to CIPN; they used the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v. 3.0) and the self-reported Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity (FACT/GOG-Ntx) subscale.

The researchers found that there was an association for multivitamin use before diagnosis with reduced symptoms of CIPN (CTCAE-adjusted odds ratio, 0.6 [95 percent confidence interval, 0.42 to 0.87]; FACT/GOG-Ntx-adjusted OR, 0.78 [95 percent confidence interval, 0.61 to 1]). There was a marginal inverse correlation for use during treatment with CIPN (CTCAE-adjusted odds ratio, 0.73 [95 percent confidence interval, 0.49 to 1.08]; FACT/GOG-Ntx-adjusted odds ratio, 0.77 [95 percent confidence interval, 0.6 to 0.99]). There was no significant correlation for other supplement use, either before diagnosis or during treatment, with CIPN.

"Multivitamin use could be a surrogate for other related behaviors that are the actual drivers of the association with reduced CIPN," the authors write.

The study was partially funded by Amgen.

Abstract/Full Text (subscription or payment may be required)